Zalunfiban: Innovative First Contact Therapy for STEMI

Created using ChatSlide

This presentation will address the CELEBRATE Trial, focusing on the swift-acting antiplatelet agent, Zalunfiban, in patients with ST-Elevation Myocardial Infarction (STEMI). Notably, current oral P2Y12 inhibitors are limited by delayed absorption. The phase 3 trial was conducted across eight countries with 2,467 participants, assessing efficacy and safety endpoints. Results demonstrated Zalunfiban's capability to enhance artery patency and reduce adverse outcomes at 30 days, with bleeding...